Understanding the epidemiology of metabolic dysfunction-associated steatotic liver disease is essential for its management: need for attention to accurate diagnostic coding and classification

참고문헌 (9)

1. Younossi ZM, "Epidemiology of metabolic dysfunction-associated steatotic liver disease", Clin Mol Hepatol (2024)[DOI]
2. Park JW, "Evolving epidemiology of non-alcoholic fatty liver disease in South Korea : incidence, prevalence, progression and healthcare implications from 2010 to 2022", Korean J Intern Med, 39, pp.931~944 (2024)
3. Lee HH, "Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease", Gut, 73, pp.533~540 (2024)
4. Quek J, "Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 8, pp.20~30 (2023)
5. Kalligeros M, "Prevalence of steatotic liver disease(MASLD, MetALD, and ALD)in the United States : NHANES 2017-2020", Clin Gastroenterol Hepatol, 22, pp.1330~1332 (2024)
6. Targher G, "MASLD : a systemic metabolic disorder with cardiovascular and malignant complications", Gut, 73, pp.691~702 (2024)
7. Kalligeros M, "Metabolic dysfunction-associated steatotic liver disease and its link to cancer", Metabolism, 160, pp.156004~ (2024)
8. Chen YT, "Long-term risks of cirrhosis and hepatocellular carcinoma across steatotic liver disease subtypes", Am J Gastroenterol (2024)[DOI]
9. Kim GA, "Critical appraisal of metabolic dysfunction-associated steatotic liver disease : Implication of Janus-faced modernity", Clin Mol Hepatol, 29, pp.831~843 (2023)

관련 논문AI추천